Business Context and Reporting Period
This Form 8-K is filed by Gemphire Therapeutics Inc. (not Metavia Inc.) on May 8, 2018. The report serves to furnish the press release detailing financial results for the first quarter ended March 31, 2018. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not reproduced in the provided text.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. It only confirms the issuance of the Q1 2018 results press release.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, or specific risk factors. It notes that the information furnished pursuant to Item 2.02 is not deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the actual financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the Press Release dated May 8, 2018).
- Confirm the discrepancy between the request metadata ("Metavia Inc.") and the filing registrant ("Gemphire Therapeutics Inc.").
- Review the full press release for any forward-looking statements or operational updates not summarized in this 8-K cover page.